253 related articles for article (PubMed ID: 20022936)
1. Breakthrough bacteraemia with a susceptible Enterococcus faecalis during tigecycline monotherapy.
Parsonage M; Shah S; Moss P; Thaker H; Meigh R; Balaji A; Elston J; Barlow G
J Antimicrob Chemother; 2010 Feb; 65(2):370-4. PubMed ID: 20022936
[No Abstract] [Full Text] [Related]
2. Tigecycline-resistant Enterococcus faecalis associated with omeprazole use in a surgical patient.
Cordina C; Hill R; Deshpande A; Hood J; Inkster T
J Antimicrob Chemother; 2012 Jul; 67(7):1806-7. PubMed ID: 22454491
[No Abstract] [Full Text] [Related]
3. Chronic bacterial prostatitis and relapsing Enterococcus faecalis bacteraemia successfully treated with moxifloxacin.
van Nieuwkoop C; Visser LG; Groeneveld JH; Kuijper EJ
J Infect; 2008 Feb; 56(2):155-6. PubMed ID: 18083235
[No Abstract] [Full Text] [Related]
4. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient.
Werner G; Gfrörer S; Fleige C; Witte W; Klare I
J Antimicrob Chemother; 2008 May; 61(5):1182-3. PubMed ID: 18285315
[No Abstract] [Full Text] [Related]
5. Tigecycline: a novel glycylcycline antibiotic.
Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
[TBL] [Abstract][Full Text] [Related]
6. Bacteremia caused by Pantoea agglomerans and Enterococcus faecalis in a patient with colon cancer.
Christakis GB; Perlorentzou SP; Aslanidou M; Savva L; Zarkadis IK
J BUON; 2007; 12(2):287-90. PubMed ID: 17600887
[TBL] [Abstract][Full Text] [Related]
7. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin.
Cunha BA; Mickail N; Eisenstein L
Heart Lung; 2007; 36(6):456-61. PubMed ID: 18005808
[TBL] [Abstract][Full Text] [Related]
8. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
Mohr JF; Friedrich LV; Yankelev S; Lamp KC
Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
[TBL] [Abstract][Full Text] [Related]
9. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection.
Munoz-Price LS; Lolans K; Quinn JP
Clin Infect Dis; 2005 Aug; 41(4):565-6. PubMed ID: 16028170
[No Abstract] [Full Text] [Related]
10. Comparative in vitro antimicrobial activity of tigecycline against clinical isolates of vancomycin-resistant enterococcus.
Yemisen M; Demirel A; Mete B; Kaygusuz A; Mert A; Tabak F; Ozturk R
Indian J Med Microbiol; 2009; 27(4):373-4. PubMed ID: 19736414
[No Abstract] [Full Text] [Related]
11. Endocarditis after ciprofloxacin therapy for enterococcal pyelonephritis with bacteremia.
McDonald GR
J Tenn Med Assoc; 1993 Dec; 86(12):527-8. PubMed ID: 8295423
[No Abstract] [Full Text] [Related]
12. Bacteremia caused by an Enterococcus faecalis isolate with high-level linezolid resistance in a teenager with Crohn's disease.
Lopez Marti MG; Jhaveri R
Pediatr Infect Dis J; 2009 Jul; 28(7):663-4. PubMed ID: 19451857
[TBL] [Abstract][Full Text] [Related]
13. Gentamicin-resistant Enterococcus faecalis sequence type 6 with reduced penicillin susceptibility: diagnostic and therapeutic implications.
Guardabassi L; Larsen J; Skov R; Schønheyder HC
J Clin Microbiol; 2010 Oct; 48(10):3820-1. PubMed ID: 20702669
[No Abstract] [Full Text] [Related]
14. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.
Lewis JS; Owens A; Cadena J; Sabol K; Patterson JE; Jorgensen JH
Antimicrob Agents Chemother; 2005 Apr; 49(4):1664-5. PubMed ID: 15793168
[No Abstract] [Full Text] [Related]
15. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
Abb J
Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
[No Abstract] [Full Text] [Related]
16. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
[TBL] [Abstract][Full Text] [Related]
17. Non-susceptibility to tigecycline in enterococci from hospitalised patients, food products and community sources.
Freitas AR; Novais C; Correia R; Monteiro M; Coque TM; Peixe L
Int J Antimicrob Agents; 2011 Aug; 38(2):174-6. PubMed ID: 21664110
[TBL] [Abstract][Full Text] [Related]
18. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
Schafer JJ; Goff DA; Stevenson KB; Mangino JE
Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of tigecycline and rifampin alone and in combination against Enterococcus faecalis biofilm infection in a rat model of ureteral stent.
Minardi D; Cirioni O; Ghiselli R; Silvestri C; Mocchegiani F; Gabrielli E; d'Anzeo G; Conti A; Orlando F; Rimini M; Brescini L; Guerrieri M; Giacometti A; Muzzonigro G
J Surg Res; 2012 Jul; 176(1):1-6. PubMed ID: 21704328
[TBL] [Abstract][Full Text] [Related]
20. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
